Abstract
Background
Non-steroidal anti inflammatory drugs (NSAIDs) are thought to account for almost 25% of all reported adverse drug reactions, primarily gastrointestinal (GI) toxicity. Selective cyclo-oxygenase-2 (COX-2) inhibitors have been shown to preferentially inhibit activity of the COX-2 enzyme, which maintains anti-inflammatory activity but reduces GI toxicity.
Objective
To determine the degree of switching from non-selective NSAIDs to COX-2 inhibitors and to examine the factors that were associated with switching.
Methods
The General Medical Services prescription database (1.2 million people) was examined for NSAID prescriptions from December 1999 through November 2001. All those receiving non-selective NSAIDs and those switching to selective COX-2 inhibitors after at least 1 month on a non-selective NSAID were identified (non-switchers and switchers, respectively). Age, sex, dose of non-selective NSAID and co-prescribing of anti-peptic ulcer (anti-PU) drugs were considered between switchers and non-switchers, and odds ratios (OR) calculated using logistic regression. The effect of chronic use (≥3 months prescription of a non-selective NSAID during the study period) on switching was also evaluated.
Results
A total of 81,538 of 480,573 patients (17%) initially prescribed non-selective NSAIDs were switched to COX-2 inhibitors during the study. The elderly (65 years or older) were more likely to be switched to a COX-2 inhibitor [OR=1.81, 95% confidence interval (CI) 1.79, 1.84]. Women were also more likely to be switched to COX-2 inhibitor therapy (OR=1.25, 95% CI 1.23, 1.27). Previous but not subsequent prescribing of anti-PU drugs was also associated with switching. Chronic users showed similar switching patterns.
Conclusions
Prescribers are more likely to switch older female patients and those with a past history of peptic ulcers from non-selective NSAIDs to COX-2 inhibitors. This suggests that doctors take risk factors into consideration when prescribing NSAIDs. The relatively low rate of switching may suggest that prescribers still have concerns over the place of COX-2 inhibitors and reserve their use to those patients particularly at risk of NSAID-induced GI toxicity.
Similar content being viewed by others
References
Chan FKL, Leung WK (2002) Peptic-ulcer disease. Lancet 360:933–941
NICE Appraisal Team (2000) The clinical effectiveness and cost effectiveness of celecoxib, rofecoxib, meloxicam and etodolac (COX-II inhibitors) for rheumatoid arthritis and osteoarthritis. National Institute for Clinical Excellence at www.nice.org.uk
Langman MJ, Weil J, Wainright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG (2000) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075–1078
Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. NEJM 340:1888–1899
Beejay U, Wolfe MM (1999) Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan? Gastroenterology 117:1002–1014
Kaplan-Machlis B, Klostermeyer BS (1999) The cyclooxygenase 2 inhibitors: safety and effectiveness. Ann Pharmacother 33:979–988
Nimesulide (1999) Irish Medicines Board Drug Safety Newsletter, Issue No. 8
Annual Report (2001) General Medical Services (Payments) Board, Dublin
Feely J, Chan R, McManus J, O'Shea B (1999) The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16:175–181
ATC index with DDD's (2003) WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway
Williams D, Kelly A, Carvalho M, Feely J (1998) Effect of the British warning on contraceptive use in the general medical service in Ireland. Ir Med J 91:202–203
Bjorkman DJ (1999) Current status of non-steroidal drug (NSAID) use in U.S: risk factors and frequency of complications. Am J Med 107:3S–10S
Walker AM, Chan K-W, Yood RA (1992) Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 45:187–195
Langman M, Kahler KH, Kong SX, Zhang Q, Finch E, Bentkover JD, Stewart EJ (2001) Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 10:517–524
Chan FL, Hung LCT, Suen BY, Wu JCY, Lee KC, Leung VKS, Hui AJ, Leung WK, Wong VWS, Chung S, Sung JJY (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. New Engl J Med 347:2104–2110
"Let the facts speak for themselves", Company Prescribing Information for Aulin (Nimuslide 100 mg) Helsinn Birex Pharmaceuticals, Dublin
Meloxicam (1998) Irish Medicines Board Drug Safety Newsletter, Issue No. 7
Acknowledgement
We would like to thank the General Medical Services (Payments) Board for providing us with the data on which this study is based.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bennett, K., Teeling, M. & Feely, J. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 59, 645–649 (2003). https://doi.org/10.1007/s00228-003-0661-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0661-8